teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 3 Projects Releases Packages Wiki Activity Actions 1

auto-fix: strip 2 broken wiki links
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-29 04:38:07 +00:00
parent 99a99e75af
commit 799b90b715
2 changed files with 2 additions and 2 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
View file

@ -51,7 +51,7 @@ Aon's commercial claims data (employer-sponsored insurance) shows strong adheren
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* *Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20*
OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely when international GLP-1 prices are dropping 50-90% but US prices remain patent-protected at $1,300/month through 2033. This creates structural access failure where coverage loss and price compression move in opposite directions for the population with highest metabolic disease burden. OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely when international GLP-1 prices are dropping 50-90% but US prices remain patent-protected at $1,300/month through 2033. This creates structural access failure where coverage loss and price compression move in opposite directions for the population with highest metabolic disease burden.

2
inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md
View file

@ -45,7 +45,7 @@ Published in *Circulation: Cardiovascular Quality and Outcomes*, 2024. Large US
**Context:** Search confirmed from multiple sources: PMC/CVQO trends study, JAHA adoption study, Amgen press release data. The pattern is consistent across data sources and time periods. **Context:** Search confirmed from multiple sources: PMC/CVQO trends study, JAHA adoption study, Amgen press release data. The pattern is consistent across data sources and time periods.
## Curator Notes ## Curator Notes
PRIMARY CONNECTION: [[Session 13 claim candidate: access-mediated pharmacological ceiling]]; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss PRIMARY CONNECTION: Session 13 claim candidate: access-mediated pharmacological ceiling; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss
WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source
EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly. EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly.